AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05108428 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Participants will receive varying doses of radiotherapy based on MRI guidance, beginning at 28-33 fractions (1.8 Gray units) .
Study NCT05108428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX regimen
Description: Standard of Care FOLFOX regimen consists of 8 cycles (each cycle is 14 days) of 5-fluorouracil, leucovorin, and oxaliplatin. Dosage is as follows: Oxaliplatin 85 mg/m\^2 IV over 2 hours day 1 each cycle. Leucovorin (optional) 400 mg/m\^2 IV over 2 hours day 1 each cycle. 5-fluorouracil bolus\* (optional) 400 mg/m\^2 IV push day 1 of each cycle, and 5-fluorouracil infusion 2400 mg/m\^2 IV continuous infusion over 46 hours day 1 each cycle.
Study NCT05257109 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water Concentration 1
Description: E-liquid containing 36mg/ml pronated nicotine will be administered with no alteration to water concentration.
Study NCT06124963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WX390
Description: WX390 tablet, 0.9 mg once a day
Study NCT06124963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 240 mg, Day 1, every 3 weeks
Study NCT05287386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib
Description: The patients will receive 13.5 mg of pemigatinib once a day (QD) orally following a 2-week administration/1-week interruption regimen. They will be dosed until disease progression or intolerable toxicity. During treatment, clinical tumor imaging evaluation will be performed according to RECIST v1.1 every 6 weeks (± 7 days) and then every 9 weeks (± 7 days) after week 48. Safety will be assessed according to NCI-CTCAE 5.0.
Study NCT05659771 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Food properties manipulation to alter eating behavior and food and energy intake
Description: Food properties of commercially available food products
Study NCT05257109 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water Concentration 2
Description: E-liquid containing 36mg/ml pronated nicotine will be administered with 5% total water concentration of e-liquid.
Study NCT05659771 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food properties manipulation to alter eating behavior and food and energy intake
Description: Food properties of commercially available food products
Study NCT05257109 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water Concentration 3
Description: E-liquid containing 36mg/ml pronated nicotine will be administered with 10% total water concentration of e-liquid.
Study NCT05257109 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water Concentration 4
Description: E-liquid containing 36mg/ml pronated nicotine will be administered with 20% total water concentration of e-liquid.
Study NCT05168943 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nylon (Polyamide) Epidural Catheter
Description: Nylon (Polyamide) Epidural Catheter
Study NCT05168943 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Polyurethane Epidural Catheter
Description: Polyurethane Epidural Catheter
Study NCT05726110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Given PO
Study NCT05726110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Homoharringtonine
Description: Given per standard of care
Study NCT05726110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Given per standard of care
Study NCT05726110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given per standard of care
Study NCT05726110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte Colony-Stimulating Factor
Description: Given per standard of care
Study NCT05726110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclacinomycin
Description: Given per standard of care
Study NCT05621317 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PVX-108
Description: PVX108 comprises a mixture of peptides that represent sequences from peanut allergens
Study NCT05621317 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo comprises the formulation vehicle without peptides
Study NCT04812548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sabatolimab
Description: Sabatolimab was administered at a low dose (Safety run-in (Part 1) cohort 1) or a high dose (Safety run-in (Part 1) cohort 2) via i.v. infusion over 30 minutes on Day 8 of every treatment cycle. Cycle = 28 days
Study NCT04812548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine
Description: A standard dose of azacitidine was given subcutaneously or intravenously every day for seven consecutive days on days 1-7 of a confirmed treatment cycle. In keeping with standard clinical practice, the alternative schedules for five consecutive days on days 1-5, followed by a two day break, then two consecutive days on days 8-9 was permitted (alternative schedule).
Study NCT04812548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venetoclax
Description: Venetoclax film-coated tablets was administered at a dose of 400 mg orally or corresponding reduced dose for concomitant use with P-gp inhibitors or moderate or strong CYP3A4 inhibitors, once a day, from C1D1 to C1D14 during the treatment cycle. No ramp-up for venetoclax was necessary.
Study NCT05570214 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Virtual reality device will be viewing calming narrated scenarios with relaxing music of walking through a forest, along a beach, through a Chinese garden, a winter landscape or taking off in a spaceship or snorkeling through a reef
Study NCT06491264 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial electrical stimulation
Description: We will administer active transcranial electrical stimulation in one of the 4 active stimulation conditions and 1 sham stimulation condition.
Study NCT06491264 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial electrical stimulation
Description: We will administer active transcranial electrical stimulation in one of the 4 active stimulation conditions and 1 sham stimulation condition.
Study NCT05299359 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TAK-019
Description: TAK-019 intramuscular injection
Study NCT04780776 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UVB treatment
Description: 5 weeks of UVB titration to determine individual's UVB sensitivity followed by 16 weeks of UVB exposure intervention
Study NCT04780776 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham comparator
Description: 5+16 weeks of visible light exposure
Study NCT06504290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VV119 Placebo （in healthy adult subjects）
Description: VV119 0.5 mg Group:2 subjects will receive VV119 Placebo 0.5 mg, orally once daily for 14 days.~VV119 1 mg Group:2 subjects will receive VV119 Placebo 1 mg, orally once daily for 14 days.~VV119 2 mg Group:2 subjects will receive VV119 Placebo 2 mg, orally once daily for 14 days.~VV119 4 mg Group:2 subjects will receive VV119 Placebo 4 mg, orally once daily for 14 days.
Study NCT06504290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VV119 （in healthy adult subjects）
Description: VV119 0.5 mg Group:6 subjects will receive VV119 0.5 mg, orally once daily for 14 days.~VV119 1 mg Group:6 subjects will receive VV119 1 mg, orally once daily for 14 days.~VV119 2 mg Group:6 subjects will receive VV119 2 mg, orally once daily for 14 days.~VV119 4 mg Group:6 subjects will receive VV119 4 mg, orally once daily for 14 days.
Study NCT06504290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VV119(in adult patients with schizophrenia)
Description: VV119 2 mg Group:6 subjects will receive 2 0.5mgVV119 capsules on the first four days, then take 1 2mgVV119 capsules and 1 0.5mg VV119 Placebo from the fifth day to the 28th day， orally once daily, VV119 4 mg Group:6 subjects will receive 2 0.5mgVV119 capsules on the first four days, take 1 2mgVV119 capsules and 1 0.5mg VV119 Placebo from the fifth day to the seventh day , then 2 2mgVV119 capsules and 1 0.5mg VV119 Placebo from the eighth day to the 28th day ,orally once daily.
Study NCT06504290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VV119 Placebo （in adult patients with schizophrenia）
Description: VV119 2 mg Group:2 subjects will receive 1 0.5mgVV119 capsules and 1 0.5mg VV119 Placebo on the first four days, then take 1 2mgVV119 Placebo and 1 0.5mg VV119 capsules from the fifth day to the 28th day， orally once daily, VV119 4 mg Group:2 subjects will receive 1 0.5mgVV119 capsules and 1 0.5mg VV119 Placebo on the first four days, take 1 2mgVV119 Placebo and 1 0.5mg VV119 capsules from the fifth day to the seventh day , then 2 2mgVV119 Placebo and 1 0.5mg VV119 capsules from the eighth day to the 28th day ,orally once daily.
Study NCT05774080 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: Observational
Study NCT05319652 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain self-management program
Description: Each week for eight weeks, participants are invited to complete self-directed lessons on particular themes. The program covers goal setting, stress management through relaxation, breathing and mindfulness, pacing, physical activity, thoughts and emotions, sleep, nutrition, flare-up management, and planning. Through pain education, positive testimonials from individuals with CNCP applying the suggested strategies, reflective activities, goal setting and monitoring, and the gradual development of a personal plan, the program supports self-efficacy building to manage CNCP.
Study NCT04492488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRG002
Description: Administrated intravenously
Study NCT06439134 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pulmonary Ultrasound, Respiratory Function Test
Description: Volunteers underwent pulmonary ultrasound and respiratory function test
Study NCT05359146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 161Tb-DOTA-LM3
Description: 161Tb-DOTA-LM3 is a therapeutic medicinal product with three main components, namely (a) Terbium-161 (161Tb), a beta minus-, gamma- and Auger-/conversion electron-emitting radionuclide with a half-life of 6.96 days; (b) DOTA, a chelator that allows stable complexation of 161Tb; and (c) LM3, an antagonistic SST analogue which binds to SST2 receptors (SST2 receptor antagonist).~All doses are presented as a sterile aqueous solution for i. v. infusion with renal protection.
Study NCT05359146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-DOTATOC
Description: 177Lu-DOTATOC = 177Lu-edotreotide is a therapeutic medicinal product with three main components (a) Lutetium-177 (177Lu), a beta minus and gamma--emitting radionuclide with a half-life of 6.65 days; (b) DOTA, a chemical chelator that allows stable complexation of 177Lu; and (c) TOC (= \[Tyr\]3-octreotide) an agonistic somatostatin analogue which binds to SST2 and much less to SST5 receptors (SST2 receptor agonist).~All doses are presented as a sterile aqueous solution for i. v. infusion with renal protection.
Study NCT04461912 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eye Scan Ultrasound System (ESUS)
Description: • For the ultrasonic signals acquisitions, an ophthalmic probe working in A-mode scan, must be coupled to the cornea. To reduce the discomfort generated by coupling the probe, topical anaesthesia (oxybuprocaine hydrochloride) will be applied before starting acquisitions. However, if the participant has some known contraindication to this anaesthetic, in replacement, a disposable neutral contact lens will be used as coupling medium between the probe and the cornea.~The acquisitions are initiated through a starting button in the system's user interface, and the probe must be kept by few seconds for automatic signals records. During this period, signals are visualized in the user interface. Finally the probe is uncoupled, and the acquired signals are saved.
Study NCT04461912 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Eye Scan Ultrasound System (ESUS)
Description: • For the ultrasonic signals acquisitions, an ophthalmic probe working in A-mode scan, must be coupled to the cornea. To reduce the discomfort generated by coupling the probe, topical anaesthesia (oxybuprocaine hydrochloride) will be applied before starting acquisitions. However, if the participant has some known contraindication to this anaesthetic, in replacement, a disposable neutral contact lens will be used as coupling medium between the probe and the cornea.~The acquisitions are initiated through a starting button in the system's user interface, and the probe must be kept by few seconds for automatic signals records. During this period, signals are visualized in the user interface. Finally the probe is uncoupled, and the acquired signals are saved.
Study NCT05872113 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Hs-hWE cream
Description: The cream was applied to the faces of subjects, the left facial area was put on the 0.5% Hs-WE cream.
Study NCT05872113 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cream
Description: The cream was applied to the faces of subjects, the right facial area was put on the placebo cream.
Study NCT05311111 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: distal radial artery approach
Description: Procedure: Use of radial artery for access for a coronary angiography or intervention After preparation and local anesthesia, the operator will puncture the distal radial artery in the dorsum of the hand or the anatomical snuff-box. Then a sheath will be placed. A cocktail combining Risordan®, Loxen® and unfractionated heparin will be injected through the sheath. a wire will be introduced. At the end of the procedure, the sheath will be removed immediately and hemostasis by compression will be carried out with an elastic band for 12 hours. The choice of limb side, sheath, catheters will be chosen according to the operator's discretion.
Study NCT05311111 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional radial artery approach
Description: Procedure: conventional radial access for a percutaneous coronary intervention After preparation and local anesthesia, the operator will puncture the proximal radial artery at the conventional site in distal forearm. Then a sheath will be placed. A cocktail combining Risordan®, Loxen® and unfractionated heparin will be injected through the sheath. a wire will be introduced. At the end of the procedure, the sheath will be removed immediately and hemostasis by compression will be carried out with an elastic band for 12 hours. The choice of limb side, sheath, catheters will be chosen according to the operator's discretion.
Study NCT04892082 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Moment
Description: The Mindful Moment program is a web-based self-guided cognitive-behavioral intervention to reduce parenting stress, targeting postpartum mothers. It consists of 6 weekly modules, each module targeting a specific thematic content, and providing mothers with both information and specific therapeutic strategies (with a strong focus on the third wave of cognitive-behavioral techniques) to address each thematic content. Modules are sequential.
Study NCT04892082 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Waiting-List Control (WLC)
Description: The control group only receive the intervention at the end of the intervention group.
Study NCT05367570 — intervention group
Intervention type: BEHAVIORAL
Intervention: Cross-sectional observational study
Description: The first work package of this project is an explanatory cross-sectional study with no intervention.
Study NCT04869475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arsenic trioxide
Description: This is a single-arm study with all patients receiving arsenci trioxide.
Study NCT06249438 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD20/BCMA-directed CAR-T cells
Description: Autologous 2nd generation CD20/BCMA-directed CAR-T cells, single infusion intravenously
Study NCT04998396 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAV9 BBP-812
Description: Sterile solution for injection for 1-time use via volumetric infusion pump
Study NCT05745441 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Dinner
Description: Dinner before DLMO
Study NCT05745441 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Late Dinner
Description: Dinner after DLMO
Study NCT05745441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Early Dinner tracer
Description: Stable isotope of oral \[2H31\] palmitate to measure fat oxidation, given with dinner before DLMO
Study NCT05460338 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: native form of Vitamin D.
Study NCT05397769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envafolimab Plus Chemoradiotherapy
Description: Envafolimab was administrated with 300mg each time, every three weeks for a total of 22 cycles since the first day of induction chemotherapy.
Study NCT05711121 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transforaminal epidural steroid injection
Description: Fluoroscopy-guided transforaminal epidural injection for radicular pain resulting from a disc herniation.
Study NCT05711121 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Caudal epidural steroid injection
Description: Fluoroscopy-guided caudal epidural injection for radicular pain resulting from a disc herniation.
Study NCT06532084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib 200 mg bid for 168 days starting in the time fram between engraftment with neutrophils > 1.0 x 10\^9/L, white blood cells> 1.5 x 10\^9/L, platelets> 1.5 x 10\^9/L and day+100 after allogeneic hematopoietic cell trnaplantation
Study NCT05957965 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wii fit
Description: Nintendo Wii console (Nintendo Co., Ltd, Kyoto, Japan) is the main power unit of Nintendo Wii Fit. Its software includes an interactive video games that is played with a handheld, wireless remote that senses motion and requires the participant to mimic the action of their on - screen character. These games are played using a special Wii balance board in order to perform activities like yoga, balance and aerobics. The Wii remote is the primary controller for Nintendo's Wii console. The motion sensing capability is the main feature of it. It allows the user to interact with and manipulate items on screen via pointing.
Study NCT05957965 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strengthening, proprioceptive exercises.
Description: -Strengthening exercise: Ankle Dorsiflexion and Plantar Flexion \& inversion and eversion Strengthening with Exercise Bands~-Proprioceptive exercise using wobble board
Study NCT05957965 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strengthening, proprioceptive exercises.
Description: -Strengthening exercise: Ankle Dorsiflexion and Plantar Flexion \& inversion and eversion Strengthening with Exercise Bands~-Proprioceptive exercise using wobble board
Study NCT06579950 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cool roof
Description: Cool roofs are a sunlight reflecting roof coating that can reduce indoor temperature. Cool roofs have high solar reflectance (reflecting the ultraviolet and visible wavelengths of sunlight, reducing heat transfer to the surface of a roof) and high thermal emittance (radiating absorbed solar energy).
Study NCT05173896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil 20 MG
Description: Daily dose of oral over-encapsulated tadalafil tablets (20 mg) for three months.
Study NCT05173896 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily dose of oral over-encapsulated placebo tablets for three months.
Study NCT06627283 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IMT
Description: Description: A pressure threshold loading device will be used: the POWERbreathe Medic (load range 10-90 cmH2O). Participants will be instructed to exhale passively during normal tidal breathing through the training device (until functional residual capacity) and to perform deep inspirations against the external load. The first week, the resistance will be fixed at 30% of the baseline measured maximal inspiratory pressure (MIP). Participants will be instructed to increase the resistance by 10% of the baseline set resistance each week.
Study NCT06627283 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EMT
Description: A pressure threshold loading device will be used: the POWERbreathe Ex1 EMT Medic (load range 10-90 cmH2O) or POWERbreathe Ex1 EMT MR (load range 35-175 cmH2O) depending on their baseline MEP measurement. Participants will be instructed to inhale quietly during normal tidal breathing through the training device and to perform rapid and deep exhalation against the external load. The first week, the resistance will be fixed at 30% of the baseline measured MEP. Participants will be instructed to increase the resistance by 10% of the baseline set resistance each week.
Study NCT06627283 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: A pressure threshold loading device will be used: the POWERbreathe Ex1 EMT Medic or MR, but with the resistance mechanism inside removed and replaced by a plastic ball. The same instructions will be given as for the EMT group, except that there will be no or minimal resistance (less than 6 cmH2O). There will be no change in resistance over the weeks.
Study NCT06709898 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive job accommodation
Description: Job accommodation focused on the cognitive aspects at work